viewMotif Bio PLC

Motif Bio in a strong position to build pipeline says chief

Graham Lumsden, chief executive of Motif Bio PLC (LON:MTFB) says the company “accomplished a lot” last year, leaving the company “in a very strong position now”.

So much so, the company is in the market for new antibiotics to add to its pipeline after making significant progress with iclaprim, its next-generation drug targeting hard-to-treat infections.

Lumsden also says the company should be ready to list on the Nasdaq market this year, with Motif already in negotiations with banks, and he adds that there are signs that markets are “starting to become a little bit more sensible” with the biotech index up around 26% so far this year.

Quick facts: Motif Bio PLC

Price: 0.616 GBX

Market: AIM
Market Cap: £2.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018


Holding(s) in Company

3 days, 18 hours ago

Holding(s) in Company

1 week, 4 days ago

Total Voting Rights

1 week, 4 days ago

Holding(s) in Company

2 weeks, 6 days ago

Directorate Changes

3 weeks, 1 day ago

Result of General Meeting

3 weeks, 5 days ago

2 min read